Merck (MRK +1.9% premarket) says one of its two migraine drugs was largely safe and effective in...

|About: Merck & Co Inc. (MRK)|By:, SA News Editor

Merck (MRK +1.9% premarket) says one of its two migraine drugs was largely safe and effective in a Phase III trial, but pulled the second due to reports of liver problems. (PR)